Skip to main
VYGR
VYGR logo

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc. is poised for future revenue growth due to its TRACER platform, which is advancing collaborations toward clinical trials expected in the 2030s. The company demonstrated promising preclinical results, such as VY1706 achieving significant reductions in tau messenger RNA and protein levels in non-human primates, with a favorable safety profile compared to existing AAV delivery methods. Additionally, data from the NeuroShuttle platform indicates enhanced central nervous system exposure duration, further establishing Voyager's competitive edge in gene therapy for neurological diseases.

Bears say

Voyager Therapeutics Inc faces a challenging financial outlook due to a combination of limited cash reserves, which may hinder its ability to fund ongoing clinical trials and research endeavors. Additionally, the company's reliance on a narrow pipeline centered around AAV-based gene therapies raises concerns about the potential for delayed or unsuccessful product development, impacting future revenue streams. Lastly, increasing competition within the gene therapy sector could further strain Voyager's market position, contributing to a negative sentiment surrounding its stock performance.

Voyager Therapeutics (VYGR) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 6 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.